Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals ...